{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "A small group of people with Parkinson's disease had been pleading for months with the biotechnology company Amgen: Let them resume taking an experimental drug that the patients said had helped them but which the company said was ineffective and possibly dangerous. Yesterday Amgen gave its answer: no. The company said it would not make the drug available to the four dozen patients who had participated in its clinical trials, even though the Food and Drug Administration had left the door open for it to do so.", "headline": {"main": "Patients in Test Won't Get Drug, Amgen Decides"}, "abstract": "Amgen decides not to make experimental drug available to four dozen patients with Parkinson's disease who participated in clinical trials; says that besides exposing patients to unnecessary risks, to let them continue treatment would only generate false hopes and may hinder development of improved versions of drug (M)", "print_page": "1", "word_count": 1220, "_id": "4fd25df38eb7c8105d80c7ee", "snippet": "A group of people with Parkinson's disease that had taken a drug as part of a trial pleaded with Amgen to allow them to resume taking it, but the company said no.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2005/02/12/business/12amgen.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "AMGEN INCORPORATED"}, {"name": "organizations", "value": "AMGEN INC"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "PARKINSON'S DISEASE"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "TESTS AND TESTING"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Andrew", "rank": 1, "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2005-02-12T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "Metropolitan Desk", "lead_paragraph": "A rare strain of H.I.V. that is highly resistant to virtually all anti-retroviral drugs and appears to lead to the rapid onset of AIDS was detected in a New York City man last week, city health officials announced on Friday. It was the first time a strain of H.I.V. had been found that both showed resistance to multiple drugs and led to AIDS so quickly, the officials said. While the extent of the disease's spread is unknown, officials called a news conference to say that the situation is alarming.", "headline": {"main": "Rare and Aggressive H.I.V. Reported in New York", "kicker": "HEALTH ALERT IN NEW YORK: OVERVIEW"}, "abstract": "Health officials say rare strain of HIV that is highly resistant to anti-retroviral drugs and appears to lead to rapid onset of AIDS has been detected in New York City man, who had unprotected sex with other men on multiple occasions while using crystal methamphetamine; say it is first time strain of HIV has been found that shows resistance to multiple drugs and leads to AIDS so quickly; say situation is alarming, but some AIDS specialists outside New York express skepticism about alarm; diagram shows how HIV replicates, and points where drugs can act (M)", "print_page": "1", "word_count": 1588, "_id": "4fd25df38eb7c8105d80c7f1", "snippet": "Officials are concerned by the detection of a rare strain of H.I.V. that appears to lead to the rapid onset of AIDS, but some experts are skeptical about the alarm.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2005/02/12/health/12aids.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "glocations", "value": "NEW YORK CITY"}, {"name": "subject", "value": "ACQUIRED IMMUNE DEFICIENCY SYNDROME"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS)"}, {"name": "subject", "value": "METHAMPHETAMINES"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "DRUG ABUSE AND TRAFFIC"}, {"name": "subject", "value": "HOMOSEXUALITY"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Marc", "rank": 1, "lastname": "SANTORA"}, {"firstname": "Lawrence", "middlename": "K.", "lastname": "ALTMAN", "rank": 2, "role": "reported", "organization": ""}], "original": "By MARC SANTORA and LAWRENCE K. ALTMAN; Donald G. McNeil Jr. contributed reporting for this article"}, "document_type": "article", "pub_date": "2005-02-12T00:00:00Z", "section_name": "Front Page; Health; New York and Region"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "A day after Canadian officials suspended the use of a hyperactivity drug amid reports of deaths associated with its use, Senator Charles E. Grassley of Iowa contended that United States health officials had asked the Canadian regulators not to do so. Senator Grassley, a Republican, said on Thursday that the Food and Drug Administration had made the request of Canadian health officials because the F.D.A. could not handle another ''drug safety crisis.'' Mr. Grassley said he was basing his contentions on reports from whistle-blowers within the agency.", "headline": {"main": "Senator Says F.D.A. Asked Canada Not to Suspend Drug"}, "abstract": "Sen Charles Grassley says FDA officials asked Canadian regulators not to pull hyperactivity drug Adderall XR from market because agency could not handle another 'drug safety crisis'; bases contention on reports from whistle-blowers within FDA; Dr Robert Peterson, Health Canada official, disputes statement and FDA declines to respond directly; FDA is allowing drug to continue to be sold in US, and says there is little evidence that it caused 20 deaths that precipitated Canada's recall; Grassley demands that FDA answer questions about discussions officials may have had with Canadians about drug; Shire Pharmaceuticals maintains drug is safe and effective; photo (M)", "print_page": "18", "word_count": 994, "_id": "4fd245f98eb7c8105d7e0735", "snippet": "Canadian officials suspended the use of a hyperactivity drug amid reports of deaths associated with its use.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2005/02/11/politics/11drug.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "GRASSLEY, CHARLES E"}, {"name": "glocations", "value": "CANADA"}, {"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "organizations", "value": "SHIRE PHARMACEUTICALS GROUP"}, {"name": "subject", "value": "ACCIDENTS AND SAFETY"}, {"name": "subject", "value": "WHISTLE-BLOWERS"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "CHILDREN AND YOUTH"}, {"name": "subject", "value": "ADDERALL (DRUG)"}, {"name": "subject", "value": "REGULATION AND DEREGULATION OF INDUSTRY"}, {"name": "subject", "value": "RECALLS AND BANS OF PRODUCTS"}, {"name": "subject", "value": "ATTENTION DEFICIT HYPERACTIVITY DISORDER"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Gardiner", "rank": 1, "lastname": "HARRIS"}, {"organization": "", "role": "reported", "firstname": "Benedict", "rank": 2, "lastname": "CAREY"}], "original": "By GARDINER HARRIS and BENEDICT CAREY; Gardiner Harris reported from Washington for this article, and Benedict Carey from New York"}, "document_type": "article", "pub_date": "2005-02-11T00:00:00Z", "section_name": "Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "Health & Fitness", "lead_paragraph": "The injectable contraceptive sold as Depo-Provera is popular with adolescent girls and young women, but has been shown to reduce bone density during this crucial period of growth. A study released yesterday found, however, that those losses appear to be reversed when the drug is discontinued. The study, published in The Archives of Pediatrics & Adolescent Medicine, compared the findings to the substantial but largely transient effect on bone density that accompanies breast-feeding.", "headline": {"main": "Your Bones on Birth Control", "kicker": "VITAL SIGNS: PATTERNS"}, "abstract": "Dr Delia Scholes of Group Health Cooperative, Seattle, leads study that shows using Depo-Provera, injectable contraceptive favored by many girls and young women, reduces bone density; condition appears temporary and bone health is found to return after drug is discontinued; study is published in Archives of Pediatrics and Adolescent Medicine (S)", "print_page": "6", "word_count": 260, "_id": "4fd2571a8eb7c8105d8012bc", "snippet": "Bone density reduction from an injectable contraceptive appears to be reversed when the drug is discontinued, a new study found.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2005/02/08/health/08patt.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "SCHOLES, DELIA"}, {"name": "organizations", "value": "ARCHIVES OF PEDIATRICS AND ADOLESCENT MEDICINE"}, {"name": "organizations", "value": "GROUP HEALTH COOPERATIVE"}, {"name": "subject", "value": "SEX"}, {"name": "subject", "value": "BONES"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "DEPO-PROVERA (DRUG)"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "BIRTH CONTROL AND FAMILY PLANNING"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "John", "rank": 1, "lastname": "O'NEIL"}], "original": "By JOHN O'NEIL"}, "document_type": "article", "pub_date": "2005-02-08T00:00:00Z", "section_name": "Health"}, {"type_of_material": "News", "blog": [], "news_desk": "Health & Fitness", "lead_paragraph": "Total knee replacement is now one of the nation's leading orthopedic operations, and it promises to become even more popular as the population ages (and grows heavier) and the body's most vulnerable joints fail to withstand the punishment of decades of use and abuse. Debilitating wear-and-tear arthritis is the major reason that knee bones are being replaced by two-pound pieces of metal in people who wish to remain mobile, pain-free and physically active in their later years.", "headline": {"main": "A New Set of Knees Comes at a Price: A Whole Lot of Pain", "kicker": "PERSONAL HEALTH"}, "abstract": null, "print_page": "7", "word_count": 1626, "_id": "4fd2a5dd8eb7c8105d88d961", "snippet": "Total knee replacement is now one of the nation's leading orthopedic operations, and it promises to become even more popular as the population ages (and grows heavier) and the body's most vulnerable joints fail to withstand the punishment of decades...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://query.nytimes.com/gst/fullpage.html?res=9D02E5D9133AF93BA35751C0A9639C8B63", "multimedia": [], "subsection_name": null, "keywords": [], "byline": {"person": [{"firstname": "Jane", "middlename": "E.", "lastname": "BRODY", "rank": 1, "role": "reported", "organization": ""}], "original": "By JANE E. BRODY"}, "document_type": "article", "pub_date": "2005-02-08T00:00:00Z", "section_name": "Health"}], "meta": {"hits": 5, "offset": 0, "time": 54}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}